ALISPORIVIR (ALV) PLUS PEG-INTERFERON/RIBAVIRIN (PR) IN HCV G1 TREATMENT-EXPERIENCED PATIENTS ACHIEVES PRIMARY ENDPOINT WITH SUPERIOR EFFICACY AT TREATMENT WEEK 12 COMPARED TO RETREATMENT WITH PR

被引：5

作者：

Alberti, A. ^{[1
]}

Chuang, W. -L. ^{[2
]}

Flisiak, R. ^{[3
]}

Mazzella, G. ^{[4
]}

Horban, A. ^{[5
]}

Goeser, T. ^{[6
]}

Calistru, P. ^{[7
]}

Buti, M. ^{[8
]}

Davis, G. ^{[9
]}

Gong, Y. ^{[10
]}

Avila, C. ^{[11
]}

Kao, J. -H. ^{[12
,13
]}

机构：

[1] Univ Padua, Padua 10764, Italy

[2] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Kaohsiung, Taiwan

[3] Med Univ Bialystok, Bialystok, Poland

[4] Az Osp Bologna Policl S Orsola Malpighi, Bologna, Italy

[5] SP ZOZ Wojewodzki Szpital Zakazny, Klin Obserwacyjno Zakazna, Warsaw, Poland

[6] Univ Klin Koln, Klin Gastroenterol & Hepatol, Cologne, Germany

[7] Ctr Diagnost Si Tratament Dr Viktor Babes, Bucharest, Romania

[8] Med Interna Hosp Vall DHebron, Barcelona, Spain

[9] Baylor Coll Med, Dallas, TX USA

[10] Beijing Novartis Pharma Co Ltd, Beijing, Peoples R China

[11] Novartis Pharma AG, Basel, Switzerland

[12] Natl Taiwan Univ Hosp, Taipei, Taiwan

[13] Natl Taiwan Univ, Coll Med, Taipei, Taiwan

来源：

关键词：

D O I：

10.1016/S0168-8278(12)61417-2

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

1406

引用

页码：S553 / S554

页数：2